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1 |  INTRODUCTION
We present a case of a 74‐year‐old female treated with 
Nivolumab for metastatic non‐small cell lung cancer, who 
presented with diarrhea three weeks after Nivolumab had 
been discontinued. A diagnosis of immune‐mediated colitis 
was treated with three days of intravenous corticosteroids and 
resulted in prompt resolution of her symptoms.
Nivolumab is a fully humanized IgG4 monoclonal anti-
body directed against the programed cell death 1 (PD‐1) re-
ceptor; which is approved for use in advanced melanoma and 
locally advanced or metastatic non‐small cell lung cancer 1 
Currently, the United States Food and Drug Administration 
(FDA) has approved the use of nivolumab for advanced mel-
anoma, renal cell carcinoma (RCC), and non‐small cell lung 
cancer (NSCLC).2
2 |  CASE REPORT
A 74‐year‐old female was admitted with a three week history 
of diarrhea, abdominal pain, and associated acute weight loss 
of 10 kg.
The patient had a known diagnosis of non‐squamous non‐
small cell lung cancer, anaplastic lymphoma kinase (ALK) 
and epidermal growth factor receptor (EGFR) mutation neg-
ative, PD‐1 status unknown, with distal metastases to both 
brain and bone. Initial treatment had been initiated with four 
cycles of Cisplatin/Pemetrexed, with subsequent maintenance 
therapy of Pemetrexed. Due to disease progression, second 
line treatment in the form of Nivolumab was instigated. Four 
cycles of Nivolumab were completed, but was unfortunately 
discontinued due to further disease progression.
Three weeks after discontinuing Nivolumab the patient re-
ported frequent diarrhea. They complained of diarrhea around 
seven times per day; with night rising, associated abdominal 
pain, poor appetite, and weight loss. Laboratory tests on ad-
mission found a hemoglobin, white cell, and platelet count 
within the normal range, an albumin of 30 g/L (35‐50 g/L), a 
CRP of 11 mg/L (0‐10 mg/L), and normal thyroid function.
Microbiological testing included stool cultures (includ-
ing Clostridium Difficile), CMV DNA PCR and adenovirus 
DNA PCR, all of which were negative. A computed tomogra-
phy (CT) scan demonstrated no abnormality of the bowel or 
vasculature, no significant abdominal lymphadenopathy and 
no pathological findings within the pelvis.
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Key Clinical Message
Nivolumab is associated with a number of immune‐regulated adverse events, includ-
ing immune‐mediated colitis and may present following the discontinuation of treat-
ment. Current guidance suggests lower doses of methylprednisolone; however, we 
described faster resolution of the patient's symptoms compared to previous reported 
cases, using higher dosing, thereby minimizing hospitalization.
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Colonoscopy showed generalized erythematous, friable, 
and edematous mucosa, with the colon and ileal mucosa 
looking evenly affected with edema and blurring of the nor-
mal vascular pattern (Figure 1).
Biopsies from the cecum, descending colon, sigmoid 
colon, and rectum showed diffuse chronic active inflam-
mation. In the more proximal biopsies, there was also fo-
cally increased subepithelial collagen membrane thickness 
with associated degenerative change of surface epithe-
lium (Figure 2). Colonic crypts demonstrated regenerative 
change but with normal architecture and increased apoptosis 
(Figure 3). Based on these findings and in the absence of 
any confounding infective pathogen being identified, a diag-
nosis of Nivolumab‐induced immune‐mediated colitis was 
suggested.
3 |  TREATMENT
Given her poor nutritional state as a consequence of limited 
enteral intake and a catabolic disease process, she was com-
menced on parenteral nutrition while investigations were 
completed. The patient was treated with three days of in-
travenous corticosteroids (1 g methylprednisolone) and the 
reintroduction of enteral nutrition. This resulted in prompt 
resolution of the patient's symptoms and parenteral nutrition 
was discontinued. She has not had any sustained or taper-
ing regime of corticosteroid or immunomodulatory therapy 
on discharge but has not had a recrudescence of symptoms 
prior to deterioration in her health and death secondary to 
progression of her non‐small cell lung cancer a few months 
after discharge.
4 |  DISCUSSION
T‐cell activation by Nivolumab causes an enhanced immune 
response and is subsequently associated with immune‐reg-
ulated adverse events (irAEs) such as immune‐mediated 
colitis.
In one meta‐analysis, Wang and colleagues demon-
strated that in patients treated with the PD‐1 signaling in-
hibitors, the overall incidence of irAEs was 26.82% (95% 
CI, 21.73‐32.61).2 Within this analysis, they highlighted 
that diarrhea was the most frequent irAEs in patients treated 
with nivolumab with an incidence of approximately 10‐13%. 
Significant colitis was determined in <1% of individuals on 
the drug. A similar meta‐analysis from Wei and Luo con-
cluded that all‐grade colitis was reported at a frequency was 
between 0.6% and 3.6%, with severe colitis frequency of 
0.3%‐2.5%. This did not distinguish between nivolumab and 
pembrolizumab therefore these results should be interpreted 
with caution; however, it certainly reinforces the notion of a 
class effect of these agents.3
Histologically, it may be challenging to delineate features 
of PD‐1 related colitis from that of other pathological pro-
cesses, in the absence of accurate drug history. In a study 
of 37 gastrointestinal biopsies of 20 patients on anti‐ PD‐1 
therapy, the most common findings in colonic biopsies were 
lamina propria expansion and increase in intraepithelial 
neutrophils. Other findings in the order of prevalence were 
crypt architectural distortion, neutrophilic crypt abscesses, 
F I G U R E  1  A/B Colonoscopy image 
displaying: generalized erythematous, 
friable and edematous mucosa, with the 
colon and ileal mucosa looking evenly 
affected with edema and blurring of the 
normal vascular pattern
(A) (B)
F I G U R E  2  Low power slide showing surface epithelium with 
marked lymphocytic infiltration and underlying collagen membrane
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increased apoptosis. However, some of these features maybe 
encountered in ischemic colitis collagenous colitis.4
In relation to onset, median time of onset of symptoms 
from trial data is around six to seven weeks but has been re-
ported to range from zero to ninety weeks.5-7 Within the pub-
lished literature and case studies, there appears to be evidence 
that withholding anti‐PD1 therapy and initiating treatment 
with glucocorticoids (0.5‐2 mg/kg/d methylprednisolone de-
pendent on the grade), generally improves symptoms within 
1‐2 weeks.3,5,7 Although some refractory cases have been de-
scribed, with the need for initiation of other immunomodula-
tory therapies such as infliximab and vedolizumab.7-9
This case clearly demonstrates a patient with onset of 
symptoms three weeks after treatment discontinuation and a 
total of nine weeks after Nivolumab had been commenced. 
It seeks to highlight the need to consider immune‐mediated 
colitis in cases despite previous discontinuation of therapy 
including those with seemingly irrelevant exposure intervals.
Given the relative novel nature and limited longitudinal 
experience of using drug modality, there remain questions 
around treatment modalities. Current guidance7,10 recom-
mends lower doses of methylprednisolone, however we de-
scribed faster resolution of the patient's symptoms compared 
to previous reported cases thereby minimizing hospitaliza-
tion. Additionally, it is tempting to suggest that patients may 
not require continued immunosuppressive therapy in order 
to maintain remission; however, a longer duration of follow‐
up will be necessary to substantiate this. Consensus for the 
use of lower doses of steroids relates to concerns regard-
ing the use of higher dose steroids due to hypothesis that 
their immunosuppressive properties and potential effect on 
T‐cell function, may lead to a decrease in the efficacy of 
nivolumab. Current evidence assessing corticosteroid use 
for the management of immune‐related adverse events do not 
support that they affect overall survival or time to treatment 
failure.11,12 However, a recent retrospective study of patients 
with melanoma who had ipilimumab‐induced hypophysitis 
that was treated with glucocorticoids showed that those who 
received higher doses (average daily dose of >7.5 mg pred-
nisone) had reduced survival.13 A further study also showed 
a relationship between corticosteroid use of ≥10 mg of pred-
nisone prior to starting treatment with PD1 blockade ther-
apy, in patients with non‐small cell lung cancer, and poorer 
outcomes including reduced progression‐free survival and 
overall survival.14 Therefore, suggesting that higher doses of 
steroids or exposure prior to treatment with anti‐PD1 ther-
apy may negatively effect checkpoint inhibitors anti‐tumor 
efficacy.
Importantly, the diagnosis of PD‐1 related colitis is en-
tirely dependent on accurate drug reconciliation, given that 
the histological features of colitis associated with immune 
checkpoint inhibitors are non‐specific, often mimicking other 
colitides including infectious colitis, IBD, GVHD, ischemic 
colitis, and other drug‐related variants. It is also imperative 
to appreciate the wide temporal variation with which these 
cases may present thereby ensuring a low threshold for con-
sideration of immunosuppressant therapy.
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